EPIDEMIOLOGY OF HTLV-III IN INTRAVENOUS DRUG ABUSERS

这项建议是一项正在进行的流行病学研究的继续 静脉注射吸毒者中HIV-1感染率较高。本研究 建议： 1)估计艾滋病毒-1抗体在以下人群中的发生率 静脉注射吸毒者； 2)对静脉注射吸毒阳性病例进行病例对照研究 和血清阴性对照； 3)估计血清流行、血清事件和 血清阴性静脉注射吸毒者；以及 4)进行生存分析，以估计 血清转换至死亡的时间或研究的一般结束时间 并确定与生存和生存相关的预后因素 死亡。 在最初的赠款中跟踪的700名静脉注射吸毒患者的队列 将构成本次续集的主要研究样本。按顺序 为了解决目标1、3和4，这700名静脉注射吸毒者已经 在药物治疗计划中进行血清状态检测将是 每隔6个月随访一次，为期2.5年。当与 数据来自原始赠款，3.5至4.5年的随访数据 将可供分析。此外，来自艾滋病的静脉注射吸毒者 降低风险计划将与700至 积累足够的病例进行病例对照研究--目标2。 这个项目分为四个阶段。在第一阶段，原始的 基线HIV-1AB检测为阴性的静脉注射吸毒者队列将 每隔6个月重新筛查一次血清转换以确定 血清转换(成为HIV AB+)的比例。在第二阶段， 血清转换(血清事件病例)的个人将被汇集 随着风险降低计划中的血清事件病例增加 病例对照研究。四个对照(血清阴性 受试者)将从血清阴性者中随机选择 游泳池。第三阶段将使用后续数据来估计道德比率 在原始队列中的子组中。阶段4将执行 生存分析，估计相对存活率并确定 影响生存的预后因素。

This proposal is a continuation of an ongoing epidemiologic study of HIV-1 infection amount intravenous drug users. This study proposes to: 1) Estimate the incidence of antibodies to HIV-1 among a cohort of IVDUs; 2) Conduct a case-control study of incident seropositive IVDU cases and seronegative controls; 3) Estimate mortality rates for seroprevalent, seroincident and seronegative IVDUs; and 4) Conduct survival analysis to estimate relative survival from time of seroconversion to death or the common closing of he study and to determine prognostic factors that related to survival and death. The cohort of 700 IVDUs that is being followed in the initial grant will form the primary study sample for this continuation. In order to address Aims 1, 3 and 4, this cohort of 700 IVDUs who have been tested for sero-status while in drug treatment programs will be followed at 6 month intervals for 2.5 years. When combined with data from the original grant, 3.5 to 4.5 years of follow-up data will be available for analysis. In addition, IVDUs from an AIDS risk reduction program will be pooled with the cohort of 700 to accrue sufficient cases to carry out the case-control study-AIM 2. There are four phases to this project. In phase 1, the original cohort of IVDUs who tested negative at baseline for HIV-1 AB will be rescreened at 6 month intervals for seroconversion to determine the proportion who seroconvert (become HIV AB+). In phase 2, individuals who seroconvert (seroincident cases) will be pooled with seroincident cases from the risk reduction program to accrue cases for the case-control study. Four controls (seronegative subjects) per case will be randomly selected from the seronegative pool. Phase 3 will use follow-up data to estimate morality rates among subgroups in the original cohort. Phase 4 will perform survival analysis, estimate relative survival and determine prognostic factors for survival.